文献速递银屑病与炎症性皮肤病

性别与银屑病系统治疗结局的关联:两国多中心前瞻性非干预登记研究

Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study.
PubMed 文献 · Br J Dermatol · 2021-06-22

该研究基于PsoBest和SDNTT两个登记库,纳入2007至2016年间5346例中重度银屑病患者,评估系统抗银屑病治疗的性别差异。结果显示女性在3、6、12个月PASI应答率及DLQI改善≥4的比例均显著高于男性,生物制剂和非生物制剂亚组中女性PASI≤3应答也优于男性。

要点

  • 女性系统治疗3、6、12个月PASI应答率均显著高于男性。
  • 女性DLQI改善≥4的比例在3、6、12个月均显著高于男性。
  • 生物制剂组女性3、6个月PASI≤3应答显著优于男性。

核心结论

  • 女性接受系统抗银屑病治疗的结局优于男性。

研究设计与样本

  • 分析PsoBest和SDNTT两个前瞻性非干预登记库中2007至2016年注册的中重度银屑病患者,共5346例(PsoBest n=4896;SDNTT n=450)。

主要发现

  • 非生物制剂组女性12个月内PASI应答、PASI 75和PASI≤3均显著优于男性。

临床怎么用

  • 临床中应关注性别对系统抗银屑病治疗应答的潜在影响,女性可能获得更优的PASI和DLQI改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Few systematic data on sex-related treatment responses exist for psoriasis. OBJECTIVES: To evaluate sex differences with respect to systemic antipsoriatic treatment. METHODS: Data from patients with moderate-to-severe psoriasis in the PsoBest or Swiss Dermatology Network of Targeted Therapies (SDNTT) registries were analysed. Treatment response was defined as achieving a ≥ 75% reduction in Psoriasis Area and Severity Index (PASI 75) or PASI ≤ 3 at treatment months 3, 6 and 12, supplemented by patient-reported outcomes [i.e. Dermatology Life Quality Index (DLQI) ≤ 1 and delta DLQI ≥ 4]. RESULTS: In total, 5346 patients registered between 2007 and 2016 were included (PsoBest, n = 4896; SDNTT, n = 450). The majority received nonbiological treatment (67·3% male, 69·8% female). Women showed slightly higher PASI response rates after 3 (54·8% vs. 47·2%; P ≤ 0·001), 6 (70·8% vs. 63·8%; P ≤ 0·001) and 12 months (72·3% vs. 66·1%; P ≤ 0·004). A significantly higher proportion of women achieved a reduction in DLQI ≥ 4 [month 3: 61·4% vs 54·8% (P ≤ 0·001); month 6: 69·6% vs. 62·4% (P ≤ 0·001); month 12: 70·7% vs. 64·4% (P ≤ 0·002)]. Regarding PASI ≤ 3, women on biologics showed a significantly superior treatment response compared with men at 3 (57·8% vs. 48·5%; P ≤ 0·004) and 6 months (69·2% vs. 60·9%; P ≤ 0·018). Women in the nonbiological treatment group had a significantly better treatment response (PASI response, PASI 75 and PASI ≤ 3) over 12 months compared with men. CONCLUSIONS: We provide evidence that women experience better treatment outcomes with systemic antipsoriatic therapy than men.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Maul JT, Augustin M, Sorbe C, et al. Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study. Br J Dermatol. 2021. PMID: 33837519. doi:10.1111/bjd.20387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。